Citable filing context

ABBV filing events and research context

Server-rendered

ABBV's research view summarizes recent SEC filing context, starting with other from May 12, 2026.

ABBV filing events and research context
FiledItemContext
May 12, 2026otherAbbVie Inc. submitted matters to a vote of its security holders on May 8, 2026.
Apr 29, 2026earningsAbbVie Inc. reported its quarterly earnings results.
Apr 3, 2026guidance_updateAbbVie updated 2026 EPS guidance to $13.96-$14.16, reflecting a $744 million acquired IPR&D expense.
Apr 29, 2026Guidance: adjusted_diluted_eps14.08 to 14.28
Apr 3, 2026Guidance: adjusted_diluted_eps13.96 to 14.16
Apr 3, 2026Guidance: adjusted_diluted_eps2.56 to 2.60
May 8, 2026mda_quarterlyAbbVie executed significant share repurchases during the first quarter of 2026, acquiring a total of 4,623,720 shares. The bulk of this activity occurred in March, with 4,621,835 shares purchased at an average price of $230.40, largely under a publicly announced program. Minor repurchases also took place in January (976 shares at $222.49) and February (909 shares at $223.56), with some shares allocated to the employee stock purchase plan. Following these transactions, approximately $1.83 billion remained authorized for future share repurchases. For the quarter ended March 31, 2026, no directors or officers adopted, modified, or terminated any Rule 10b5-1 or non-Rule 10b5-1 trading arrangements. The filing further details the company's employee equity compensation framework, including Performance-Vested Restricted Stock Units, Performance Share Awards, and Non-Qualified Stock Options, outlining their vesting conditions, forfeiture clauses, and tax withholding mechanisms, which are integral to AbbVie's long-term incentive structure.
Feb 20, 2026businessAbbVie is a global, diversified research-based biopharmaceutical company with leading positions in immunology, neuroscience, oncology, and aesthetics. Its immunology portfolio includes key growth drivers Skyrizi (risankizumab) and Rinvoq (upadacitinib), with U.S. patent protection for Rinvoq extending to April 2037 (with pediatric exclusivity) and Skyrizi to 2033. Humira (adalimumab), a former blockbuster, now faces direct global biosimilar competition. Neuroscience products feature Vraylar for psychiatric disorders, Botox Therapeutic for various conditions, and Ubrelvy/Qulipta for migraine. Oncology includes Imbruvica and Venclexta for blood cancers, alongside newer therapies like Elahere and Epkinly. The aesthetics segment, acquired from Allergan, is anchored by Botox Cosmetic and the Juvederm Collection. The company operates in a highly competitive environment, facing significant pricing pressures and biosimilar erosion. The Inflation Reduction Act (IRA) presents a material risk, with Imbruvica, Vraylar, Linzess, and Botox already selected for government price negotiation, potentially impacting future revenues. AbbVie invests heavily in research and development, supplementing internal efforts with strategic acquisitions and licensing to maintain its pipeline of innovative therapies. Products are distributed globally, primarily through wholesalers and direct sales to healthcare providers.

Source: SEC EDGAR filing text and events; period May 12, 2026; filed May 12, 2026.

Continue research

Keep researching ABBV

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →
AMGN
AMGEN INC
$186.59B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →